Why It Matters
Nascent Biotech Inc. filed a new client registration with American Defense International Inc., signed Oct. 20, covering defense issues; the company has no prior lobbying disclosures on record. The sole lobbyist named is Van Hipp Jr., Chair of American Defense International Inc.
Broader Context
Nascent Biotech develops human monoclonal antibodies for cancer, with Pritumumab as its lead candidate; the FDA has granted Pritumumab orphan-drug designation for gliomas and pancreatic cancer, according to a February 2025 shareholder letter published by the company.
The fiscal year 2026 National Defense Authorization Act includes provisions authorizing a Department of Defense (DOD) biotechnology supply-chain resiliency program, a DOD biotechnology office, and a commercialization program, along with a prohibition on executive-agency procurement from certain biotechnology providers, according to the text of S. 1071 on Congress.gov.
Between The Lines
A February 2026 Government Accountability Office report found that DOD had invested $965.2 million since 2021 in biotechnology projects and domestic biomanufacturing supply chains. At an Aug. 4, Subcommittee on Health Care hearing on building a resilient health care future with biotechnology, Michelle Rozo, Vice Chair of the National Security Commission on Emerging Biotechnology, urged DHS and the Cybersecurity and Infrastructure Security Agency to designate biotech as a critical sector. At the same hearing, Sen. Todd Young (R-IN) noted that biotech used for life-saving treatments "can be leveraged or parlayed into bioindustrial applications useful to war fighters."
An X post from the @ChinaSelect account on Sept. 30 described the bipartisan Biotech Investment National Security Act, which the post attributed to Chairman Moolenaar, as a bill that would subject biotech deals with China to national security reviews and ban partnerships with entities tied to human rights abuses.
Competitive Landscape
Registration filings for AT Process Technologies, signed Oct. 20, and Honeywell Aerospace, signed Oct. 19, both carry a defense issue code. Other defense-issue registrations signed Oct. 20 include Lynch Regenerative Medicine LLC through McAllister & Quinn LLC and Omega Air Refueling Services Inc. through Augustus Global Advocacy LLC.
The Bottom Line
Nascent Biotech Inc. filed a new client registration on October 20, hiring American Defense International Inc. to lobby on defense, with Van Hipp Jr. listed as the firm's chair and the sole named lobbyist.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article
